Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.74 |
| ▸ | CES1 | P23141 | 1/20 | 0.74 |
| ▸ | LCK | P06239 | 1/20 | 0.58 |
| ▸ | FYN | P06241 | 1/20 | 0.58 |
| ▸ | DAO | P14920 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.39 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.39 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8182714 | 0.85 | CES2 (1.00) | CES2CES1LCKFYNDAO | |
| SCHEMBL826805 | 0.81 | — | — | |
| Hydrochloric Acid SCHEMBL8804487 | 0.79 | — | — | |
| Hydrochloric Acid SCHEMBL17164880 | 0.79 | CES2 (0.62) | CES2CES1LCKFYNDAO | |
| SCHEMBL3957096 | 0.79 | CES2 (0.77) | CES2CES1LCKFYNDAO | |
| SCHEMBL1384047 | 0.78 | CES2 (0.56) | CES2CES1LCKFYNDAO | |
| Water SCHEMBL27497754 | 0.77 | CES2 (0.74) | CES2CES1LCKFYNDAO | |
| SCHEMBL28495546 | 0.77 | CES2 (0.74) | CES2CES1LCKFYNDAO | |
| SCHEMBL2166098 | 0.75 | CES2 (0.71) | CES2CES1LCKFYNDAO | |
| SCHEMBL5069541 | 0.74 | CES2 (0.68) | CES2CES1LCKFYNDAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109749058-B | Anthracene bithiophene imide polymer and preparation method and application thereof | 中国科学院化学研究所 | 2020-12-01 | — | — | CN | disclosed |
| CN-109749058-A | A kind of anthra Dithiophene imide polymer and the preparation method and application thereof | 中国科学院化学研究所 | 2019-05-14 | — | — | CN | disclosed |
| EP-1636217-B1 | 2-IMIDAZO-BENZOTHIAZOLES AS ADENOSINE RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 2008-09-03 | — | — | EP | disclosed |
| EP-1450796-B1 | BENZOTHIAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-04-09 | — | — | EP | disclosed |
| US-7122545-B2 | Imidazo-benzothiazoles | HOFFMANN-LA ROCHE INC. (US) | 2006-10-17 | — | — | US | disclosed |
| CN-1780831-A | 2-Imidazole-Benzothiazoles as Adenosine Receptor Ligands | HOFFMANN LA ROCHE (CH) | 2006-05-31 | — | — | CN | disclosed |
| EP-1636217-A1 | 2-IMIDAZO-BENZOTHIAZOLES AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004101558-A1 | 2-IMIDAZO-BENZOTHIAZOLES AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-25 | — | — | WO | disclosed |
| US-20040229862-A1 | Imidazo-benzothiazoles | F. HOFFMAN-LA ROCHE AG (CH) | 2004-11-18 | — | — | US | disclosed |
| US-6596718-B1 | A compound of formula I has a good affinity to the A2A receptor and is useful for the treatment of diseases mediated by this receptor. | HOFFMANN-LA ROCHE INC. | 2003-07-22 | — | — | US | disclosed |
| EP-1299377-A2 | SPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-04-09 | — | — | EP | disclosed |
| WO-2002000641-A2 | SPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229862-A1 | Imidazo-benzothiazoles | ADORA1, ADORA3, ADORA2A | CES2 2869/4885CES1 1785/4885LCK 4151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.